AAAAAA
Results:
1-8
|
Results: 8
Authors:
Cohen, P
Frame, S
Citation: P. Cohen et S. Frame, The renaissance of GSK3, NAT REV MOL, 2(10), 2001, pp. 769-776
Authors:
Frame, S
Cohen, P
Biondi, RM
Citation: S. Frame et al., A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation, MOL CELL, 7(6), 2001, pp. 1321-1327
Authors:
Frame, S
Cohen, P
Citation: S. Frame et P. Cohen, GSK3 takes centre stage more than 20 years after its discovery, BIOCHEM J, 359, 2001, pp. 1-16
Authors:
Culbert, AA
Brown, MJ
Frame, S
Hagen, T
Cross, DAE
Bax, B
Reith, AD
Citation: Aa. Culbert et al., GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective andinduces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity, FEBS LETTER, 507(3), 2001, pp. 288-294
Authors:
Frame, S
Citation: S. Frame, Article about Canadian guidelines on proton pump inhibitors was misleading, BR MED J, 320(7242), 2000, pp. 1143-1143
Authors:
Frame, S
Balmain, A
Citation: S. Frame et A. Balmain, Integration of positive and negative growth signals during ras pathway activation in vivo, CUR OP GEN, 10(1), 2000, pp. 106-113
Authors:
Thomas, GM
Frame, S
Goedert, M
Nathke, I
Polakis, P
Cohen, P
Citation: Gm. Thomas et al., A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of Axin and beta-catenin, FEBS LETTER, 458(2), 1999, pp. 247-251
Authors:
Frame, S
Balmain, A
Citation: S. Frame et A. Balmain, Target genes and target cells in carcinogenesis, BR J CANC, 80, 1999, pp. 28-33
Risultati:
1-8
|